ABBOTT LABORATORIES (ABT) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Win.
63/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseABT / S&P -11.07% / 15.20% |
LoseABT / S&P ABT unavailable / 15.00% |
LoseABT / S&P ABT unavailable / 50.40% |
| 2026-Q10/3 |
LoseABT / S&P -17.64% / -4.33% |
LoseABT / S&P 6.59% / 11.30% |
LoseABT / S&P -53.51% / 27.70% |
| 2025-Q40/3 |
LoseABT / S&P -6.04% / 2.65% |
LoseABT / S&P 5.67% / 9.00% |
LoseABT / S&P -51.18% / 13.40% |
| 2025-Q32/3 |
LoseABT / S&P -1.08% / 8.12% |
WinABT / S&P 6.37% / 4.61% |
WinABT / S&P 142.25% / 13.45% |
| 2025-Q22/3 |
LoseABT / S&P 3.01% / 10.94% |
WinABT / S&P 5.85% / 4.83% |
WinABT / S&P 151.42% / 10.63% |
| 2025-Q13/3 |
WinABT / S&P 17.89% / -4.27% |
WinABT / S&P 5.00% / 4.98% |
WinABT / S&P 139.88% / 10.57% |
| 2024-Q41/3 |
LoseABT / S&P -0.32% / 2.41% |
LoseABT / S&P 4.59% / 5.25% |
WinABT / S&P 134.36% / 6.15% |
| 2024-Q32/3 |
WinABT / S&P 10.30% / 5.89% |
LoseABT / S&P 3.15% / 5.89% |
WinABT / S&P 11.90% / 6.11% |
| 2024-Q21/3 |
LoseABT / S&P -8.12% / 4.28% |
LoseABT / S&P 1.24% / 5.38% |
WinABT / S&P 8.19% / 5.12% |
| 2024-Q10/3 |
LoseABT / S&P 3.76% / 10.56% |
LoseABT / S&P -2.84% / 5.71% |
LoseABT / S&P -2.43% / 5.59% |
| 2023-Q41/3 |
WinABT / S&P 14.28% / 11.69% |
LoseABT / S&P -8.12% / 6.81% |
LoseABT / S&P -16.62% / 7.78% |
| 2023-Q30/3 |
LoseABT / S&P -10.74% / -3.27% |
LoseABT / S&P -11.26% / 7.52% |
LoseABT / S&P -33.63% / -5.03% |
| 2023-Q20/3 |
LoseABT / S&P 8.20% / 8.74% |
LoseABT / S&P -11.68% / 9.50% |
LoseABT / S&P -38.83% / -8.57% |
| 2023-Q10/3 |
LoseABT / S&P -7.35% / 7.50% |
LoseABT / S&P -6.76% / 10.77% |
LoseABT / S&P -23.67% / -15.69% |
| 2022-Q42/3 |
WinABT / S&P 14.00% / 7.56% |
LoseABT / S&P 1.34% / 11.88% |
WinABT / S&P -0.76% / -17.99% |
| 2022-Q31/3 |
LoseABT / S&P -10.55% / -4.88% |
LoseABT / S&P 6.43% / 13.47% |
WinABT / S&P 9.93% / -1.41% |
| 2022-Q22/3 |
WinABT / S&P -7.84% / -16.10% |
LoseABT / S&P 13.21% / 13.71% |
WinABT / S&P 34.93% / 11.04% |
| 2022-Q11/3 |
LoseABT / S&P -15.61% / -4.60% |
WinABT / S&P 19.22% / 15.97% |
LoseABT / S&P 35.11% / 42.23% |
| 2021-Q42/3 |
WinABT / S&P 19.60% / 11.03% |
WinABT / S&P 24.47% / 15.00% |
LoseABT / S&P 57.60% / 96.40% |
| 2021-Q33/3 |
WinABT / S&P 2.29% / 0.58% |
WinABT / S&P 31.31% / 10.77% |
WinABT / S&P 113.23% / 69.42% |
| 2021-Q22/3 |
LoseABT / S&P -2.91% / 8.55% |
WinABT / S&P 27.95% / 6.58% |
WinABT / S&P 105.20% / 51.81% |
| 2021-Q13/3 |
WinABT / S&P 9.89% / 6.17% |
WinABT / S&P 16.34% / -1.06% |
WinABT / S&P 60.30% / 7.39% |
| 2020-Q42/3 |
LoseABT / S&P 0.94% / 12.15% |
WinABT / S&P 8.48% / -3.72% |
WinABT / S&P 21.36% / -33.42% |
| 2020-Q33/3 |
WinABT / S&P 19.49% / 8.93% |
WinABT / S&P 2.76% / -2.04% |
WinABT / S&P 2.72% / -27.10% |
| 2020-Q22/3 |
LoseABT / S&P 16.35% / 20.54% |
WinABT / S&P 1.65% / -0.46% |
WinABT / S&P 6.13% / -27.11% |
| 2020-Q13/3 |
WinABT / S&P -8.77% / -19.60% |
WinABT / S&P 4.47% / 3.47% |
WinABT / S&P 34.46% / -14.75% |
| 2019-Q41/3 |
LoseABT / S&P 4.23% / 9.07% |
LoseABT / S&P 4.34% / 5.36% |
WinABT / S&P 54.89% / 2.99% |
| 2019-Q31/3 |
LoseABT / S&P -0.14% / 1.70% |
LoseABT / S&P 3.13% / 5.02% |
WinABT / S&P 275.51% / 0.21% |
| 2019-Q22/3 |
WinABT / S&P 5.63% / 4.30% |
LoseABT / S&P 4.60% / 6.64% |
WinABT / S&P 219.61% / 8.65% |
| 2019-Q11/3 |
LoseABT / S&P 11.03% / 13.65% |
LoseABT / S&P 8.01% / 8.12% |
WinABT / S&P 469.23% / 14.29% |
| 2018-Q43/3 |
WinABT / S&P -1.00% / -13.52% |
WinABT / S&P 11.64% / 9.05% |
WinABT / S&P 392.59% / 18.23% |
| 2018-Q32/3 |
WinABT / S&P 20.82% / 7.71% |
WinABT / S&P 20.96% / 10.21% |
LoseABT / S&P -61.72% / 19.06% |
| 2018-Q21/3 |
LoseABT / S&P 2.28% / 3.43% |
WinABT / S&P 25.28% / 9.03% |
LoseABT / S&P -29.17% / 14.46% |
| 2018-Q12/3 |
WinABT / S&P 5.50% / -0.76% |
WinABT / S&P 27.54% / 7.68% |
LoseABT / S&P -73.20% / 12.46% |
| 2017-Q42/3 |
WinABT / S&P 7.48% / 6.64% |
WinABT / S&P 31.35% / 7.03% |
LoseABT / S&P -71.28% / 13.82% |
| 2017-Q33/3 |
WinABT / S&P 10.38% / 4.48% |
WinABT / S&P 21.37% / 5.68% |
WinABT / S&P 40.66% / 17.57% |
| 2017-Q22/3 |
WinABT / S&P 10.13% / 3.09% |
WinABT / S&P 14.84% / 4.83% |
LoseABT / S&P -52.32% / 17.74% |
| 2017-Q12/3 |
WinABT / S&P 16.37% / 6.07% |
WinABT / S&P 9.37% / 3.67% |
LoseABT / S&P -40.12% / 13.32% |
| 2016-Q41/3 |
LoseABT / S&P -8.60% / 3.82% |
WinABT / S&P 2.20% / 2.09% |
LoseABT / S&P -67.81% / 7.05% |
| 2016-Q32/3 |
WinABT / S&P 8.24% / 3.85% |
WinABT / S&P 0.66% / 0.20% |
LoseABT / S&P -69.67% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ABT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -13.94% | 20.78% |
| Annualized return | -13.94% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ABT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -3.46% | 83.14% |
| Annualized return | -0.70% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ABT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 218.45% | 319.30% |
| Annualized return | 12.28% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |